CIK 0000730272
- Large accelerated filer
REPLIGEN CORP
Sign in to watch- Ticker
- RGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 042729386
- Phone
- +1 781-449-9560
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,976,580
- in 4 filings, $5.0M under 10b5-1 plans
Net −$4,976,580. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-04-06 | Bylund James SVP, Global Operations & IT | Sale | −360 | $204.25 | $74K | 6,324 |
| 2021-03-16 | Gebski Christine | Sale | −1,400 | $196.88 | $276K | 37,140 |
| 2021-03-12 | RYAN THOMAS F JR Director | Gift | −170 | 1,294 | ||
| 2021-03-12 | Hunt Anthony Chief Executive Officer | Sale | −914 | $188.06 | $172K | 220,950 |
| 2021-03-12 | Hunt Anthony Chief Executive Officer | Sale | −1,171 | $188.77 | $221K | 219,779 |
| 2021-03-12 | Hunt Anthony Chief Executive Officer | Sale | −4,096 | $190.17 | $779K | 215,683 |
| 2021-03-12 | Hunt Anthony Chief Executive Officer | Sale | −1,081 | $191.19 | $207K | 214,602 |
| 2021-03-12 | Hunt Anthony Chief Executive Officer | Sale | −1,378 | $192.17 | $265K | 213,224 |
| 2021-03-12 | Hunt Anthony Chief Executive Officer | Sale | −227 | $193.30 | $44K | 212,997 |
| 2021-03-12 | Hunt Anthony Chief Executive Officer | Sale | −235 | $194.08 | $46K | 212,762 |
| 2021-03-10 | KURIYEL RALF Senior VP, R&D | Exercise or conversion | +2,000 | $33.05 | $66K | 27,265 |
| 2021-03-10 | KURIYEL RALF Senior VP, R&D | Exercise or conversion | +5,850 | $33.87 | $198K | 33,115 |
| 2021-03-10 | KURIYEL RALF Senior VP, R&D | Exercise or conversion | +150 | $59.52 | $9K | 33,265 |
| 2021-03-10 | KURIYEL RALF Senior VP, R&D | Sale | −6,354 | $190.08 | $1.2M | 26,911 |
| 2021-03-10 | KURIYEL RALF Senior VP, R&D | Sale | −642 | $191.33 | $123K | 26,269 |
| 2021-03-10 | KURIYEL RALF Senior VP, R&D | Sale | −1,004 | $192.13 | $193K | 25,265 |
| 2021-03-10 | KURIYEL RALF Senior VP, R&D | Exercise or conversion · Stock Option (Right to Buy) | −2,000 | 2,000 | ||
| 2021-03-10 | KURIYEL RALF Senior VP, R&D | Exercise or conversion · Stock Option (Right to Buy) | −5,850 | 0 | ||
| 2021-03-10 | KURIYEL RALF Senior VP, R&D | Exercise or conversion · Stock Option (Right to Buy) | −150 | 3,911 | ||
| 2021-03-04 | Hunt Anthony Chief Executive Officer | Sale | −794 | $197.94 | $157K | 242,970 |
Page 29 of 42 · 832 trades